Navigation Links
PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
Date:11/19/2008

ANNAPOLIS, Md., Nov. 19 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has signed an agreement with Medison Pharma Ltd., to commercialize its biodefense products in Israel.

"The need for advanced medical countermeasures to combat the risk of terrorist attacks with biological or chemical weapons is a significant global concern," stated David P. Wright, President and Chief Executive Officer of PharmAthene. "Our allies in Israel understand the importance of procuring next generation biodefense products to protect their military and civilian populations from the threat of biological and chemical warfare."

Under terms of the exclusive, multi-year agreement, Medison Pharma will commercialize products from PharmAthene's biodefense portfolio and will be responsible for overseeing regulatory approval, marketing, and distribution activities for those products in Israel. PharmAthene will maintain all manufacturing responsibilities.

Maryland Governor Martin O'Malley, whose administration has played an integral role in supporting bioscience in Maryland and fostering business partnerships between Israel and the State of Maryland, commented, "Companies such as PharmAthene are making significant advances by developing novel products which are intended to save lives and deter terrorist attacks against our citizens. We are very proud to support these initiatives and assist Maryland companies in developing global partnerships and international markets for their products and technologies."

Commenting on today's news, Eric Richman, Senior Vice President, Business Development and Strategic Planning for PharmAthene, noted, "Governor O'Malley's vision of facilitating commercial opportunities for Maryland bioscience companies by establishing global partnerships has enab
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , SAN DIEGO, Nov. 20 Veri...l Award in the mid-size company category at the 20...nsored by the San Diego Society for Human Resource...nal human resources practices. ,, Veridiam was ...mployee-nominated companies, honored at the recent...
(Date:11/20/2009)... METTLER TOLEDO recently ...ctions Process Optimization Using At-Line Particle...ember 2, 2009. In this webinar, the application o...d to map the design space and optimize a series of...s, flow rates, and roller compaction forces. , ...
(Date:11/19/2009)..., , BLAUVELT, N.Y., Nov. 19 ...eat germ extract, responds to a press release issu...the Hungarian company for making false and self-se...n BioSciences. ,, Dr. Hidvegi stated from his ...a claim that research on Avemar does not apply to ...
(Date:11/19/2009)..., , MUNSTER, Germany, November 19 /P... they have filed on November 16th, 2009 Flibanseri...duced dyskinesia in Parkinson,s,disease for orphan...es Agency,(EMEA). Levodopa-induced dyskinesia is a...d Parkinson,s and a serious burden to some of thos...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Roller Compaction Process Optimization Using At-Line Particle Characterization 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... April 22 Renovis, Inc.,(Nasdaq: RNVS ), today a...dvisory firm, has joined ISS/Risk Metrics in recom...erger agreement with Evotec AG (Frankfurt,Stock Ex...cheduled for May,1, 2008. In the proposed merger, ...ed into the right to receive the equivalent of 1.0...
...il 22 Medarex, Inc.,(Nasdaq: MEDX ) announced to...Stanley Global Healthcare Unplugged Conference at ...vent will be webcast live and will be,available in...site at, http://www.medarex.com . An archived edit...g the event., About Medarex, Medarex is a biopha...
...il 22 Sysmex America, Inc. today,announced the su...ton, OH),beta studies for its integrated hematolog...solution, which combines the Sysmex HST-N hematolo...s, Inc. VARIANT(TM) II TURBO,Link, enables on-dema...setting. "This integrated testing solution, now fu...
Other Biology Technology:Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 2Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 3Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 2Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 3Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 4
(Date:11/23/2009)... existed for 360 million years and survived when t...hreatening to make many of them extinct, according...ogy Today . , The fungus, Batrachochytrium den...waves of amphibian extinctions in Central America ...cts over 350 amphibian species by penetrating thei...
(Date:11/23/2009)...Institute for Child Health Research has found evid...tion in pregnancy affects child behaviour in diffe...nline in the international journal Addiction . ,...s drawn from a random sample of more than 2000 mot...ter the baby,s delivery, and were then followed up...
(Date:11/23/2009)..., posing dangers to human health and the environme... new project with funding from the U.S. Environmen...nd grease that contribute to millions of overflows...s to further reduce the risk of sewage spills. , ...ems, as opposed to "combined" systems that also ha...
Breaking Biology News(10 mins):New study links alcohol in pregnancy to child behavior problems 2Lose the fat: Targeting grease to curtail sewer overflows 2DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 1DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 2DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 3BioWa and NKTT Announce Licensing of BioWas POTELLIGENT 28R 29 Technology For Use in Antibody Research and Development 14560 1BioWa and NKTT Announce Licensing of BioWas POTELLIGENT 28R 29 Technology For Use in Antibody Research and Development 14560 2BioWa and NKTT Announce Licensing of BioWas POTELLIGENT 28R 29 Technology For Use in Antibody Research and Development 14560 3Delcath Systems Inc Completes Phase III Study Enrollment 5635 1Delcath Systems Inc Completes Phase III Study Enrollment 5635 2Delcath Systems Inc Completes Phase III Study Enrollment 5635 3
...chnologies that allow scientists to quickly and ac... analysis are being creatively deployed for the fi.... , The University of Ghana, supported by the Phi...oneering the use of DNA "barcodes" to map menacing...atic filariasis (LF), commonly known as elephantia...
... Germany, April 29, 2009 / b3c newswire / - K...d its Cellular Target Profiling® technology to...r target of celecoxib (Celebrex®, Pfizer). Cel... inhibitor approved for the treatment of osteoarth...ition, celecoxib’s anti-proliferative effect...
...n University and the Donald Danforth Plant Science...ion from the U.S. Department of Energy (DOE) to do...lion, the Washington University award is the large...illion for the Donald Danforth Plant Science Cente...d. , Washington University and the Donald Danfort...
Other Biology News:DNA barcoding of mosquito species deployed in bid to end elephantiasis 2DNA barcoding of mosquito species deployed in bid to end elephantiasis 3DNA barcoding of mosquito species deployed in bid to end elephantiasis 4KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex 2DOE makes largest Danforth Campus research award in history 2DOE makes largest Danforth Campus research award in history 3DOE makes largest Danforth Campus research award in history 4DOE makes largest Danforth Campus research award in history 5
Nitrite Colorimetric Assay Kit from Molecular Probes (Invitrogen)
...ologies has been at the forefront providing advanc...ry and application of genomic information. Whether...100 or 100,000 custom oligos for microarray applic... exacting synthesis, purification, QA/QC and docum...
Cultrex 3D Culture Matrix BME from R&D Systems
Sentrix Custom-96 Expression Array Matrix (1) from Illumina
Biology Products: